Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« An Alternative View of the Solicitor General’s Joblove Brief | Main | Pharma News Briefs »

May 28, 2007

ACI "Maximizing Pharmaceutical Patent Life Cycles" Conference, June 5-6, San Francisco

American Conference Institute will hold the 2nd west coast edition of its popular "Maximizing Pharmaceutical Patent Life Cycles" conference next week in San Francisco (at the beautiful Mark Hopkins hotel).  ACI calls this "the only Hatch-Waxman conference specifically designed for the biopharmaceutical industry."

According to ACI, the conference will "bring the biopharmaceutical industry the critical information that it needs regarding the legal aspects of pharmaceutical patent life cycles.  An esteemed faculty of biopharmaceutical industry and Hatch-Waxman experts will provide targeted information and commentary especially for biopharmas."

The following talks should be particularly interesting:

  • Legislative and Regulatory Update: Patents and Politics in the 110th Congress
  • Follow-on Biologics/Biosimilars: The IP and Political Wildcard
  • Aligning Product Development, Patent Portfolio Management and Patent Life Cycle Management
  • Eye on the Supreme Court: Key Patent Cases Before the Supreme Court and Their Impact on Pharmaceutical Patent Life Cycles
  • European Roche Bolar: Understanding Its Impact on U.S. Pharmaceutical Patent Life Cycles
  • Update on FDA Activities Relative to Pharmaceutical Patent Life Cycles
  • Present Controversies and Uncertainties in Market Exclusivity (by Kurt Karst of FDA Law Blog)
  • FTC Initiatives to Promote Competition in the Pharmaceutical Industry

Additionally, two pre- and post-conference workshops are available: "Regulatory Fundamentals and IP Basics for Small Molecules and Biologics" on June 4; and "New Strategies for Obtaining Pharmaceutical Patent Extensions" on June 7.

The co-chairs of the conference are Martin A. Voet (Sr. VP & Chief IP Counsel, Allergan, Inc. and author of The Generic Challenge) and Robert C. Funsten (Shareholder, Stradling Yocca Carlson & Rauth).  Additional details and registration information are available at the conference website.

Orange Book Blog is a media partner of this conference.

Posted by Aaron Barkoff in Conferences |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.